Cerner has partnered with Claritas Genomics to develop a scalable laboratory solution for molecular diagnostics designed for next-generation sequencing workflows, aiming to advance the use of personalized medicine across the healthcare industry.
The new laboratory solution will use Cerner's Millennium Helix, which provides clinicians with instant access to genetic information following molecular data capture and will be part of Cerner's Reference Lab Network to facilitate lab ordering and results return.
"Cerner has long focused on the power of genomics and its impact to clinical processes, and this relationship will help advance the field and define a meaningful narrative in personalized medicine between the realms of research, diagnostics and clinical practice," said Dick Flanigan, senior vice president at Cerner, in a news release. "Claritas' focus on pediatrics is noteworthy, as that's when integrating genomics into clinical practice could be particularly impactful."
As part of the partnership, Cerner Capital has become a minority shareholder in Claritas, a company that was originally formed as a spin-out of Boston Children's Hospital.
More Articles on the Health IT Market:
What New York Digital Health Accelerator's First-Year Results Reveal About the Health IT Market
Nuance Shares Tumble on Poor Q1 Outlook
CareFusion Acquires GE Healthcare's Vital Signs Division for $500M